China's Ophthalmic Drugs in the Starting Stage
China's ophthalmic drugs market is in the starting stage and is now growing at a rapid and exponential growth momentum. The market size of ophthalmic drugs in China has grown from USD 1.8 billion in 2015 to USD 2.6 billion by 2019, at a CAGR of 9.3%. China's ophthalmic drugs market size is expected to grow at a faster rate than the growth of the global ophthalmic drugs market over the same period in the next five years.
The number of patients with dry eye disease is growing
Dry eye disease is one of the most common ophthalmologic diseases in China and the world. About 40% of dry eye patients suffer from moderate to severe dry eye disease, which is associated with severe pain, limitations in daily life, decreased vitality, poor overall health and frequent depression. The number of dry eye disease patients in China has grown from 195 million in 2015 to 214 million in 2019. The number of dry eye patients is expected to continue to grow due to accelerated aging and new lifestyles driven by information technology.
Environmental Changes Lead to Increase in Patients with Allergic Conjunctivitis
Allergic conjunctivitis is a common eye disease usually caused by hypersensitivity of the conjunctiva to external allergens. The number of patients with allergic conjunctivitis in China has increased from 291 million in 2015 to 294 million in 2019 due to air pollution and environmental changes.
The number of patients with glaucoma in China is expected to grow further
Glaucoma, the second leading cause of blindness globally, is a chronic and progressive disease associated with high pressure in the eye leading to optic nerve damage. The ratio of intraocular aqueous production to aqueous discharge determines intraocular pressure. Almost all glaucomas are primary glaucomas and are usually categorized as open-angle glaucoma or closed-angle glaucoma. In China, about 40% of primary glaucomas are open-angle glaucomas.
In China, the number of glaucoma patients increased from 13.4 million in 2015 to 15.3 million in 2019. Driven by accelerated population aging, the number of glaucoma patients in China is expected to grow in further.
--For more data, please refer to Analysis Report on Production, Sales Demand and Investment Forecast of Ophthalmic Drugs Industry in China by Prospect Industry Research Institute.